CareLit · DOI-Nachweis · Pneumologie
Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial
DOI 10.1055/s-2008-1074447
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ von Pawel, T Larson, S Ou, S Limentani, A Sandler, E Vokes, S Kim, K Liau, P Bycott, A Olszanski, J Schiller
ZeitschriftPneumologie
Ausgabe04/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: A correlation between vascular endothelial growth factor (VEGF), microvessel density, and prognosis has been reported in pts with NSCLC. AG is a specific VEGF receptor (VEGFR) inhibitor with picomolar potency against VEGFR 1, 2 and 3. This is an open-label, multicenter phase II study examining the efficacy and safety of single-agent AG in pts with advanced NSCLC. Methods: Pts with stage IIIB or metastati…
Zitieren
Zitierempfehlung
J von Pawel, T Larson, S Ou, S Limentani, A Sandler, E Vokes, S Kim, K Liau, P Bycott, A Olszanski, J Schiller (2008) Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. Pneumologie (04). https://doi.org/10.1055/s-2008-1074447
Mit CareLit weiterarbeiten